HBsAg was measured by enzyme immunoassay (AxSYM; Abbott Japan, Tokyo, Japan) and chemiluminescence enzyme immunoassay (CLEIA) (Fujirebio, Tokyo, Japan). The IgG class of anti-HBc was determined by radioimmunoassay (Abbott Japan). Anti-HBs was tested by enzyme immunoassay (AxSYM; Abbott Japan, Tokyo Japan). Anti-HCV was tested by CLEIA (Fujirebio, Tokyo, Japan). All serologic assays were performed according to the manufacturer's instructions.
Cleia
Manufactured by Fujirebio
Sourced in Japan
CLEIA is a laboratory equipment product manufactured by Fujirebio. It is a chemiluminescent enzyme immunoassay (CLEIA) technology that is used for the detection and quantification of various analytes in biological samples.
Automatically generated - may contain errors
Lab products found in correlation
C reactive protein (crp), by Sekisui (2 mentions)
Cholestest n hdl, by Sekisui (2 mentions)
Colestest ldl, by Sekisui (2 mentions)
Pureanto stg n, by Sekisui (2 mentions)
Eclia, by Roche (1 mentions)
Bm6010, by JEOL (1 mentions)
Nephelometric assay, by Siemens (1 mentions)
Radioimmunoassay, by Abbott (1 mentions)
Axsym, by Abbott (1 mentions)
Immobilon, by Merck Group (1 mentions)
Cellytic m cell lysis reagent, by Merck Group (1 mentions)
Fugene 6, by Promega (1 mentions)
12 protocols using cleia
1
Viral Hepatitis Serological Assays
2
Assessing Thyroid Autoantibody Levels
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Serum levels of TPO antibody were assayed by electrochemiluminescence immunoassay (ECLIA, Roche-Diagnostics K.K., Tokyo, Japan) or by chemiluminescent enzyme immunoassay (CLEIA, FUJIREBIO Inc., Tokyo, Japan). A TPO antibody titer of 16 IU/ml or more by ECLIA and 5.2 IU/ml or more by CLEIA were the cut-off values, and regarded as positive for TPO antibody. Serum levels of thyroid stimulating hormone (TSH) were determined by CLEIA (ABBOTT JAPAN Co.,Ltd, Chiba, Japan). During pregnancy, TSH was measured every 1-3 months depending on the level of the TSH. Endocrinologists adjusted the level of TSH during pregnancy to 2.5~3.0 μU/mL since the current upper limit of serum TSH at the first and second trimester is considered to be 2.5~3.0 μU/mL (Stagnaro-Green et al. 2011) .
3
HTLV-1 and Hepatitis C Serology
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
We tested the serum of participants for anti-HTLV-1 antibodies using a CLEIA (Fujirebio, Tokyo, Japan). When the results were positive, we confirmed the finding by Western blotting (BML, Tokyo, Japan). We defined the participants for whom anti-HTLV-1 antibody was detected by Western blotting as HTLV-1 seropositive. RF (DENKA SEIKEN, Tokyo, Japan) and CRP (SEKISUI MEDICAL, Tokyo, Japan) were measured with a latex agglutination immunoassay using an auto-analyzer (BM6010, JEOL, Tokyo, Japan). Anti-CCP antibody was tested using a CLEIA (SRL, Tokyo, Japan). Anti-HCV antibody was tested using a second-generation passive hemagglutination kit (Dynabott, Tokyo, Japan) or a second-generation EIA kit (Sysmex International Reagents Corporation, Kobe, Japan). Quantitative and/or qualitative detection of HCV RNA was also carried out using the Amplicor HCV monitor test ver. 1.0 or ver. 2.0 and/or the Amplicor HCV ver. 2.0 (Roche Diagnostics Systems, Tokyo, Japan) among anti-HCV-positive samples. Participants for whom HCV RNA was positive were defined as HCV infected.
4
Biomarker Quantification in Ablation Patients
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Blood was sampled from the femoral vein (FV) with an 18 gauge needle prior to the ablation procedure on the day of ablation therapy, placed immediately on ice and centrifuged at 3,000g for 15 min at 4°C. The resultant serum or plasma was aliquoted to different tubes to avoid repeated freeze–thaw cycles and stored at − 80°C till use. Serum soluble ELAM1 (sELAM1; ng/mL), soluble VCAM1 (sVCAM1; ng/mL), and soluble ICAM1 (sICAM1; ng/mL) were measured by enzyme-linked immunosorbent assay (ELISA; R&D systems, Minneapolis, MN, USA); plasma VWF activity (%) by latex agglutination immunoassay (LAIA; Siemens Healthcare Diagnostics Products GmbH, Marburg, Germany); serum soluble TM (sTM; FU/mL) by ELISA (Kyowa Pharma Chemical, Takaoka, Toyama, Japan); plasma BNP (pg/mL) by chemiluminescent enzyme immunoassay (CLEIA; Fujirebio, Shinjuku, Tokyo, Japan). The within-run reproducibility was < 8% for ELISAs and CLEIA and < 20% for LAIA. All assays were performed by investigators who were blinded to all clinical information about the participants.
5
Comprehensive Serum Lipid Profiling Protocol
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Measurements of serum lipid profile and other parameters were outsourced to SRL Co. (Tokyo, Japan). Plasma lipid was measured with a Hitachi 7350 autoanalyzer (Hitachi Co., Tokyo, Japan). LDL‐C was measured using the colestest LDL (Sekisui Medical, Tokyo, Japan) by the direct method. HDL‐C was measured using the Cholestest NHDL (Sekisui Medical) by the direct method. TG was measured using the pureanto STG‐N (Sekisui Medical) by the enzymatic method. FFA was measured using the NEFA‐SS”EIKEN” (Eiken Kagaku, Tokyo, Japan) by the enzymatic method. Furthermore, sdLDL‐C was measured using the sdLDL‐EX reagent “SEIKEN” (Denka Seiken Inc., Tokyo, Japan) by the enzymatic method. MDA LDL‐C was measured using the oxidative ELISA “Daiichi” (Sekisui Medical) by the sandwich enzyme‐linked immunosorbent assay method. ApoB‐48 was measured using a chemiluminescence enzyme immunoassay (CLEIA; Fuji Rebio Inc, Tokyo, Japan)7 . ApoB‐100 was measured using a turbidimetric immunoassay (TIA; Daiichi Kagaku, Tokyo, Japan). All samples were stored at −80°C until measurement.
6
Biomarker Measurements in NAFLD
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
After the blood collection, the blood cell count and biochemical measurements were performed at an external laboratory (SRL Inc., Tokyo) as described6 (link). The hs-CRP, the TNF-α, and the IL-6 were measured by a nephelometric assay (Siemens Healthcare Diagnostic Inc., Erlangen, Germany), an enzyme-linked immunosorbent assay (ELISA; R&D Systems Inc., Minneapolis, MN), and a chemiluminescent enzyme immunoassay (CLEIA; Fujirebio Inc., Tokyo), respectively. The HOMA-IR was calculated using the following equation28 (link): fasting blood glucose (mg/dL) × insulin (μIU/mL)/405. NAFLD was diagnosed based on our calculation of the subject’s FLI, a well-validated surrogate of hepatic steatosis, which we defined as an FLI score ≥ 6029 (link). The FLI score was calculated using the following equation29 (link): FLI = (e0.953 × loge (triglycerides) + 0.139 × BMI + 0.718 × loge (γ-GTP) + 0.053 × waist circumference − 15.745)/(1 + e 0.953 × loge (triglycerides) + 0.139 × BMI + 0.718 × loge (γ-GTP) + 0.053 × waist circumference − 15.745) × 100.
7
Serum Biomarker Analysis in Cohort Study
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
We collected venous blood at the baseline survey and sent serum samples to an external testing laboratory (SRL, Fukuoka, Japan) for analysis. Serum GGT, AST, and ALT concentrations were measured using autoanalyzers (GGT: EDC EZ scan, Tokyo, Japan; AST and ALT: Olympus AU 5431, Tokyo, Japan). Serum HBsAg and anti-HCV were assayed using a chemiluminescent immunoassay (CLIA; Dinabot, Tokyo, Japan) and a third-generation enzyme immunoassay (CLEIA; Fuji Rebio, Tokyo, Japan), respectively.
8
Chemiluminescent Immunoassay for SMRP
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
9
Serum Pepsinogen Ratio in H. pylori Eradication
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
We also determined the percentage changes in serum PG I/II ratios before and 3 months after treatment with CLEIA® (FUJIREBIO Inc, Tokyo, Japan) and established cut-off values to distinguish success from failure of H. pylori eradication. Cut-off values for percentage changes in serum PG I/II ratios were set as +40, +25 and +10% when the serum PG I/II ratio before treatment was below 3.0, above 3.0 but below 5.0 and 5.0 or above, respectively [17 (link)]. The percentage change in values was calculated as follows: percentage change = {(value 3 months after the end of treatment)–(value before treatment)}/(value before treatment)×100. The gold standard of H. pylori eradication was defined as negative by the use of a UBT performed 3 months after completion of the eradication treatment.
10
HBsAg Quantification by Chemiluminescence
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
HBsAg was measured by chemiluminescent enzyme immunoassay (CLEIA) (Fujirebio, Tokyo, Japan) and expressed as fold change compared to DMSO control.
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!